Current status and issues in genomic analysis using EUS-FNA/FNB specimens in hepatobiliary-pancreatic cancers

Yoshinori Ozono; Hiroshi Kawakami; Naomi Uchiyama; Hiroshi Hatada; Souichiro Ogawa

doi:10.1007/s00535-023-02037-z

Current status and issues in genomic analysis using EUS-FNA/FNB specimens in hepatobiliary-pancreatic cancers

J Gastroenterol. 2023 Nov;58(11):1081-1093. doi: 10.1007/s00535-023-02037-z. Epub 2023 Sep 12.

Authors

Yoshinori Ozono^#¹, Hiroshi Kawakami^#², Naomi Uchiyama¹, Hiroshi Hatada¹, Souichiro Ogawa¹

Affiliations

¹ Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki, 889-1692, Japan.
² Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki, 889-1692, Japan. hiropon@med.miyazaki-u.ac.jp.

^# Contributed equally.

Abstract

Comprehensive genomic profiling based on next-generation sequencing has recently been used to provide precision medicine for various advanced cancers. Endoscopic ultrasound (EUS)-guided fine-needle aspiration (EUS-FNA) and EUS-guided fine-needle biopsy (EUS-FNB) play essential roles in the diagnosis of abdominal masses, mainly pancreatic cancers. In recent years, CGP analysis using EUS-FNA/FNB specimens for hepatobiliary-pancreatic cancers has increased; however, the success rate of CGP analysis is not clinically satisfactory, and many issues need to be resolved to improve the success rate of CGP analysis. In this article, we review the transition from EUS-FNA to FNB, compare each test, and discuss the current status and issues in genomic analysis of hepatobiliary-pancreatic cancers using EUS-FNA/FNB specimens.

Keywords: Comprehensive genomic profiling; EUS-guided fine-needle aspiration; EUS-guided fine-needle biopsy; Endoscopic ultrasound; Hepatobiliary–pancreatic cancers.

Publication types

Review